What is MNKD's current stock price?

MNKD (MannKind Corporation) is currently trading at $3.38 with a market cap of $1.04B.

What sector is MannKind Corporation in?

MannKind Corporation (MNKD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MNKD a good stock to buy?

Analysts have a Buy consensus on MNKD with a price target of $8.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MNKD MannKind Corporation

Healthcare

$3.38+2.11%ClosedMarket Cap: $1.04B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

135.05

PEG

—

P/B

-17.60

P/S

2.89

EV/EBITDA

50.11

DCF Value

$-41.62

FCF Yield

1.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

76.0%

Operating Margin

3.7%

Net Margin

-6.6%

ROE

45.6%

ROA

-3.2%

ROIC

1.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$90.2M	$-16.6M	$—
Q4 null	$112.0M	$-15.9M	$—
FY null	$349.0M	$5.9M	$—
Q3 null	$82.1M	$8.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.25

Target (Median)

$8.50

Target Range

$6.00 - $10.00

0 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell

Wells FargoOverweight

2026-05-07

RBC CapitalSector Perform

2026-05-07

HC Wainwright & Co.Buy

2026-05-07

MizuhoOutperform

2026-05-07

WedbushOutperform

2026-03-05

Trading Activity

Insider Trades

View All

Shannon James Samueldirector

SellFri May 22

Shannon James Samueldirector

SellFri May 22

HOOPER ANTHONY Cdirector

SellFri May 22

HOOPER ANTHONY Cdirector

SellFri May 22

Grancio Jenniferdirector

SellFri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.04

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Peers